1. Ostrom QT, Price M, Neff C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015–2019. Neuro Oncol 2022; 24: v1-v95.
2.
Grochans S, Cybulska AM, Simińska D, et al. Epidemiology of glioblastoma multiforme – literature review. Cancers 2022; 14: 2412.
3.
Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 2021; 23: 1231-1251.
4.
Lathia JD, Mack SC, Mulkearns-Hubert EE, Valentim CL, Rich JN. Cancer stem cells in glioblastoma. Genes Dev 2015; 29: 1203-1217.
5.
Papavassiliou KA, Papavassiliou AG. Transcription factors in glioblastoma – molecular pathogenesis and clinical implications. Biochim Biophys Acta Rev Cancer 2022; 1877: 188667.
6.
Duclot F, Kabbaj M. The role of early growth response 1 (EGR1) in brain plasticity and neuropsychiatric disorders. Front Behav Neurosci 2017; 11: 35.
7.
Magee N, Zhang Y. Role of early growth response 1 in liver metabolism and liver cancer. Hepatoma Res 2017; 3: 268-277.
8.
Aliperti V, Sgueglia G, Aniello F, Vitale E, Fucci L, Donizetti A. Identification, characterization, and regulatory mechanisms of a novel EGR1 splicing isoform. Int J Mol Sci 2019; 20: 1548.
9.
Piatkowska-Chmiel I, Herbet M, Gawronska-Grzywacz M, Ostrowska-Lesko M, Dudka J. The role of molecular and inflammatory indicators in the assessment of cognitive dysfunction in a mouse model of diabetes. Int J Mol Sci 2021; 22: 3878.
10.
Wang B, Guo H, Yu H, Chen Y, Xu H, Zhao G. The role of the transcription factor EGR1 in cancer. Front Oncol 2021; 11: 642547.
11.
Sun SW, Fang XM, Li YF, Wang QB, Li YX. Expression and clinical significance of EGR-1 and PTEN in the pituitary tumors of elderly patients. Oncol Lett 2017; 14: 2165-2169.
12.
Zhang L, Ren R, Yang X, Ge Y, Zhang X, Yuan H. Oncogenic role of early growth response-1 in liver cancer through the regulation of the microRNA-675/sestrin 3 and the Wnt/-catenin signaling pathway. Bioengineered 2021; 12: 5305-5322.
13.
Guo S, Gao Y, Zhao Y. Neuroprotective microRNA-381 binds to repressed early growth response 1 (EGR1) and alleviates oxidative stress injury in Parkinson’s disease. ACS Chem Neurosci 2023; 14: 1981-1991.
14.
Gitenay D, Baron VT. Is EGR1 a potential target for prostate cancer therapy? Future Oncol 2009; 5: 993-1003.
15.
Knudsen AM, Eilertsen I, Kielland S, et al. Expression and prognostic value of the transcription factors EGR1 and EGR3 in gliomas. Sci Rep 2020; 10: 9285.
16.
Kyani A, Tamura S, Yang S, et al. Discovery and mechanistic elucidation of a class of protein disulfide isomerase inhibitors for the treatment of glioblastoma. ChemMedChem 2018; 13: 164-177.
17.
Ma C, Wang H, Zong G, et al. EGR1 modulated LncRNA HNF1A-AS1 drives glioblastoma progression via miR-22-3p/ENO1 axis. Cell Death Discovery 2021; 7: 350.
18.
Uthamacumaran A, Craig M. Algorithmic reconstruction of glioblastoma network complexity. iScience 2022; 25: 104179.
19.
Sperandio S, Fortin J, Sasik R, Robitaille L, Corbeil J, de Belle I. The transcription factor EGR1 regulates the HIF-1alpha gene during hypoxia. Mol Carcinog 2009; 48: 38-44.
20.
Liu C, Yao J, Mercola D, Adamson E. The transcription factor EGR-1 directly transactivates the fibronectin gene and enhances attachment of human glioblastoma cell line U251. J Biol Chem 2000; 275: 20315-20323.
21.
Laribee RN, Boucher AB, Madireddy S, Pfeffer LM. The STAT3-regulated autophagy pathway in glioblastoma. Pharmaceuticals 2023; 16: 671.
22.
Lv D, Yang K, Rich JN. Growth factor receptor signaling induces mitophagy through epitranscriptomic regulation. Autophagy 2023; 19: 1034-1035.
23.
Singh N, Miner A, Hennis L, Mittal S. Mechanisms of temozolomide resistance in glioblastoma – a comprehensive review. Cancer Drug Resist 2021; 4: 17-43.
24.
Gaspar N, Marshall L, Perryman L, et al. MGMT-independent temozolomide resistance in pediatric glioblastoma cells associated with a PI3-kinase-mediated HOX/stem cell gene signature. Cancer Res 2010; 70: 9243-9252.
25.
Chen L, Liu YC, Zheng YY, et al. Furanodienone overcomes temozolomide resistance in glioblastoma through the downregulation of CSPG4-Akt-ERK signalling by inhibiting EGR1-dependent transcription. Phytother Res 2019; 33: 1736-1747.
26.
Sakakini N, Turchi L, Bergon A, et al. A positive feed-forward loop associating EGR1 and PDGFA promotes proliferation and self-renewal in glioblastoma stem cells. J Biol Chem 2016; 291: 10684-10699.
27.
Chen DG, Zhu B, Lv SQ, et al. Inhibition of EGR1 inhibits glioma proliferation by targeting CCND1 promoter. J Exp Clin Cancer Res 2017; 36: 186.
28.
Li L, Chen X, Dong F, et al. Dihydroartemisinin up-regulates VE-cadherin expression in human renal glomerular endothelial cells. J Cell Mol Med 2018; 22: 2028-2032.
29.
Mohamad T, Kazim N, Adhikari A, Davie JK. EGR1 interacts with TBX2 and functions as a tumor suppressor in rhabdomyosarcoma. Oncotarget 2018; 9: 18084-18098.
30.
Cesana M, Tufano G, Panariello F, et al. EGR1 drives cell proliferation by directly stimulating TFEB transcription in response to starvation. PLoS Biol 2023; 21: e3002034.
31.
Kfoury N, Qi Z, Prager BC, et al. Brd4-bound enhancers drive cell-intrinsic sex differences in glioblastoma. Proc Natl Acad Sci U S A 2021; 118: e2017148118.
32.
Xu L, Peng B, Wu H, Zheng Y, Yu Q, Fang S. METTL7B contributes to the malignant progression of glioblastoma by inhibiting EGR1 expression. Metab Brain Dis 2022; 37: 1133-1143.
33.
Ferreira DA, Tayyar Y, Idris A, McMillan NAJ. A “hit-and-run” affair – a possible link for cancer progression in virally driven cancers. Biochim Biophys Acta Rev Cancer 2021; 1875: 188476.
34.
Yang T, Liu D, Fang S, Ma W, Wang Y. Cytomegalovirus and glioblastoma: a review of the biological associations and therapeutic strategies. J Clin Med 2022; 11: 5221.
35.
Athanasiou E, Gargalionis AN, Boufidou F, Tsakris A. The association of human herpesviruses with malignant brain tumor pathology and therapy: two sides of a coin. Int J Mol Sci 2021; 22: 2250.
36.
Harrison MAA, Morris SL, Rudman GA, et al. Intermittent cytomegalovirus infection alters neurobiological metabolism and induces cognitive deficits in mice. Brain Behav Immun 2024; 117: 36-50.
37.
Dziurzynski K, Chang SM, Heimberger AB, et al. Consensus on the role of human cytomegalovirus in glioblastoma. Neuro Oncol 2012; 14: 246-255.
38.
Farias K, Moreli ML, Floriano VG, da Costa VG. Evidence based on a meta-analysis of human cytomegalovirus infection in glioma. Arch Virol 2019; 164: 1249-1257.
39.
Rahbar A, Stragliotto G, Orrego A, et alC. Low levels of human cytomegalovirus infection in glioblastoma multiforme associates with patient survival; -a case-control study. Herpesviridae 2012; 3: 3.
40.
Ye L, Qian Y, Yu W, Guo G, Wang H, Xue X. Functional profile of human cytomegalovirus genes and their associated diseases: a review. Front Microbiol 2020; 11: 2104.
41.
Van Damme E, Van Loock M. Functional annotation of human cytomegalovirus gene products: an update. Front Microbiol 2014; 5: 218.
42.
Buehler J, Carpenter E, Zeltzer S, et al. Host signaling and EGR1 transcriptional control of human cytomegalovirus replication and latency. PLoS Pathog 2019; 15: e1008037.
43.
El Baba R, Herbein G. Immune landscape of CMV infection in cancer patients: from “canonical” diseases toward virus-elicited oncomodulation. Front Immunol 2021; 12: 730765.
44.
Akhtar S, Vranic S, Cyprian FS, Al Moustafa AE. Epstein-Barr virus in gliomas: cause, association, or artifact? Front Oncol 2018; 8: 123.
45.
Woodson CM, Kehn-Hall K. Examining the role of EGR1 during viral infections. Front Microbiol 2022; 13: 1020220.
46.
Zagurovskaya M, Shareef MM, Das A, et al. EGR-1 forms a complex with YAP-1 and upregulates Bax expression in irradiated prostate carcinoma cells. Oncogene 2009; 28: 1121-1131.
47.
Ahmed MM. Regulation of radiation-induced apoptosis by early growth response-1 gene in solid tumors. Curr Cancer Drug Targets 2004; 4: 43-52.
48.
Lopez CA, Kimchi ET, Mauceri HJ, et al. Chemoinducible gene therapy: a strategy to enhance doxorubicin antitumor activity. Mol Cancer Ther 2004; 3: 1167-1175.
